American Society of Gene + Cell Therapy and Pfizer Announce anIndependent Medical Education Grant RFP

Gene and Gene-modified Cell Therapies
Medical Education
I. Introduction

Competitive Grant ProgramThis Request for Proposals (RFP) is for initiatives that span multiple rare disease areas. The American Society ofGene + Cell Therapy and Pfizer Global Medical Grants are collaborating to offer a new competitive grant opportunity
focused on supporting independent medical education to increase the medical and scientific understanding of geneand gene-modified cell therapies.

About the American Society of Gene + Cell Therapy (ASGCT)The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinicalapplication of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst
for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice ofmedicine by incorporating the use of genetic and cellular therapies to control and cure human disease.
About Pfizer Global Medical Grants (GMG):
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g.,
research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that arealigned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant programme involves a publicly posted Request for Proposal (RFP) that provides
detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel(ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps
in education as outlined in the RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for thedesign, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involvedin any aspect of project development, nor the conduct of the independent education program.

[Title/Clinical Area]

II. Eligibility
Geographic Scope:

GlobalApplicant Eligibility
Criteria•

Only organizations are eligible to receive grants, not individuals or
medical practice groups.

•For projects offering continuing education credit, the requestingorganization must be accredited.

III. Requirements
Date RFP Issued

7 May 2024

Clinical Area

Gene Therapy- Rare Disease

Specific Area of Interestfor this RFP:

Projects that will be considered for support will focus on independent medical
education initiatives that will result in the measurable improvement of the
medical and scientific understanding of gene and gene-modified celltherapies to help prepare multidisciplinary teams for the integration of geneand gene-modified cell therapies into the treatment armamentarium ofeligible patients with a Rare Disease.
Proposals tailored to a specific rare disease or group of rare diseases will not
be considered.

Target Audience:

Members of multidisciplinary care teams for gene and gene modified celltherapies including but not limited to Pharmacists, Specialty Nurses, GeneticCounselors, Medical Geneticists, and other Physicians.

Expected Approximate
Monetary Range ofGrant Applications:•Individual projects requesting up to $50,000 will be considered. The
estimated total available budget related to this RFP is $150,000.

•The amount of the grant Pfizer will be prepared to fund for any projectwill depend upon the expert review panel’s evaluation of the proposal
and costs involved and will be stated clearly in the grant agreement.

1[Title/Clinical Area]

Key Dates:

How to Submit:•RFP release date: 7 May 2024•

Application Deadline: 1 July 2024•

Review of Applications by Expert Review Panel: August 2024•

Anticipated Full Proposal Notification Date: September 2024•

Grants distributed following execution of fully signed Grant Contract•

Anticipated Project Start Date: October•

Please go to www.cybergrants.com/pfizer/knowledge and sign in. Firsttime users should click “Create your password”.

•Click the “Start A New Knowledge Gap Application” button.

•In the application:
oFor the question “What type of request are you submitting?”
select Response to a Request for Proposal (RFP)

oFor the question “Are you replying to a Request for Proposal(RFP) as part of the Competitive Grant Program?” select YesoSelect the following Competitive Grant Program Name: 2024
RD G: ASGCT Gene Education•Requirements for submission:
Complete all required sections of the online application and upload yourproject proposal (see Appendix) in the General RFP Submission field.

•If you encounter any technical difficulties with the website, please clickthe “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not
be reviewed by the committee.

Questions:•If you have questions regarding this RFP, please direct them in writing
to the Pfizer Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com)
with the subject line “Gene Therapy Education.”

Grant Agreements:•If your grant is approved, your institution will be required to enter into awritten grant agreement with Pfizer. Please click here to view the coreterms of the agreement.
Pfizer has drafted the terms of these agreements to be balanced andreasonable and to further the goals of both parties. Negotiating grant
agreements requires significant resources, so please ensure that yourinstitution (including your legal department) is able and willing to abideby these terms before proceeding with submission of your application
as they will need to be accepted in their entirety.

•Review and Approval•

A specific grant program RFP uses an expert review panel (ERP) tomake final grant decisions.

2[Title/Clinical Area]

Process•The panels are comprised of professionals from the medical community
with advanced degrees and expertise in particular clinical areas, orspeciﬁc needs of a geographic region/learner group, or expertise inresearch, continuing professional development or quality improvement

Mechanism by which
Applicants will be
Notified:••

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review
period.

3

[Title/Clinical Area]

Appendix A
Proposal Requirements
Applications will be accepted via the online portal. The main section of the full proposal
document should be no longer than 12 pages in length (12-point font and 1-inch margins)
excluding Organization Detail, References, and Budget Narrative. The full proposal should be
uploaded in the portal as a single document.
Goals and Objectives•

Briefly state the overall goal of the project. Also describe how this goalaligns with the focus of the RFP and the goals of the applicant
organization(s).

•List the overall objectives you plan to meet with your project both in termsof learning and expected outcomes. Objectives should describe thetarget population as well as the outcomes you expect to achieve as aresult of conducting the project.

Assessment of Needfor the Project•

Please include a quantitative baseline data summary, initial metrics (e.g.,quality measures), or a project starting point (please cite data on gap
analyses or relevant patient-level data that informs the stated objectives)in your target area. Describe the source and method used to collect thedata. Describe how the data was analyzed to determine that a gap
existed. If a full analysis has not yet been conducted, please include a
description of your plan to obtain this information.

Target Audience•

Describe the primary audience(s) targeted for this project. Also indicate
whom you believe will directly benefit from the project outcomes.
Describe the overall population size as well as the size of your sample
population.

Project Design andMethods•

Describe the planned project and the way it addresses the establishedneed.

•If your methods include educational activities, please describe succinctly
the topic(s) and format of those activities.

•Please describe how the project submitted supports diversity, equity, andinclusion either through the study population targeted or through theproject team that is directly involved.

•Explain what measures you have taken to assure that this project idea isoriginal and does not duplicate other projects or materials alreadydeveloped.

•Describe how this project builds upon existing work, pilot projects, orongoing projects developed either by your institution or other institutions
related to this project.

Innovation

4

[Title/Clinical Area]

Evaluation andOutcomes•

In terms of the metrics used for the needs assessment, describe how you
will determine if the practice gap was addressed for the target group.
Describe how you expect to collect and analyze the data.

•Quantify the amount of change expected from this project in terms ofyour target audience.

•Describe how the project outcomes will be broadly disseminated.

Anticipated ProjectTimeline•

Provide an anticipated timeline for your project including project start/enddates

Additional Information•

If there is any additional information you feel Pfizer should be aware ofconcerning the importance of this project, please summarize hereOrganization Detail•

Describe the attributes of the institutions / organizations / associations
that will support and facilitate the execution of the project and theleadership of the proposed project. Articulate the specific role of eachpartner in the proposed project. Letters of support from partnerorganizations will be required at the Full Proposal stage only and should
not be included with the LOI.

Budget Detail•

While estimating your budget please keep the following items in mind:•oGeneral organizational running costs such as insurances, heating,lighting, rent, building maintenance may be included. Pfizer does notprovide funding for capital purchases (infrastructure expenses suchas equipment, purchases of software or software licenses,technology or bricks and mortar). Equipment hire/leasing is
acceptable and may be included in project budget. The inclusion ofthese costs cannot cause the amount requested to exceed thebudget limit set forth in the RFP.

oThe inclusion of these costs cannot cause the amount requested toexceed the budget limit set forth in the RFP.

oIt should be noted that grants awarded through GMG cannot be
used to purchase Pfizer therapeutic agents (prescription or nonprescription).

Pfizer maintains a company-wide, maximum allowed overhead rate of
28% for independent studies and projects. Please click here for details.

5